Hematology

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

A hematologist discusses the role of internal and family medicine practitioners in improving the diagnosis and management of iron deficiency.

Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.

In this video, a hematologist discusses trials and areas of advancement he is excited about in the current landscape.

In part 2 of our 5-part series, Steven Fein, MD, discusses updates in iron deficiency management from 2024.

In this video, Steven Fein, MD, discusses updates and topics of note from the American Society of Hematology annual meeting.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

At ASH 2024, Annette von Drygalski, MD, PharmD, described the paradigm shift that has taken place in hemophilia over the past decade.

Data from the PINES trial at ASH 2024 suggest eltrombopag could outperform current standard of care for platelet response in newly diagnosed pediatric ITP.

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibody’s anti-inflammatory action.

Topline results from APPULSE-PNH show the positive efficacy and safety of twice-daily oral iptacopan in adults with PNH switched from anti-C5 therapies.

Dexamethasone treatment was linked to worse clinical outcomes in patients with sickle cell disease hospitalized for COVID-19.

Anemia in heart failure with preserved ejection fraction was linked to right ventricular dysfunction in an analysis of more than 1000 patients in China.

Insufficient ferric carboxymaltose dosing and timing fail to significantly improve hemoglobin levels, suggesting gaps in perioperative anemia management.

New late-breaking ACG 2024 data supports AIMS65 as a risk factor tool for patients undergoing anticoagulant reversal.

On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.

Anemia could be a reliable sign of all-cause mortality in patients with heart failure.

A systematic review found cognitive impairment a defining characteristic of SCA, with a notable impact on individuals of all ages.

The anti-TFPI significantly reduced ABR compared to routine prophylaxis treatment in the phase 3 BASIS trial.

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.